REGN-EB3 and mAb114 reduced mortality in a clinical trial carried out during the ongoing outbreak in Democratic Republic of Congo.

Executives at a biotech that develops new antibodies argue that Ram Sasisekharan didn’t come up with the structures for at least two experimental therapies that his group has described.

The scientist and clinician helped develop a new form of cancer therapy, using a monoclonal antibody to treat head, neck, colorectal, and lung cancers.

The study will examine the efficacy of four drugs—an antiviral and three monoclonal antibodies—that are already being used to treat patients in Democratic Republic of Congo.

Some patients could suppress the virus without antiretroviral therapy for months after the drug infusions.

The number of cases in Democratic Republic of Congo’s latest outbreak of the virus has now surpassed 100.  

The monoclonal antibody, known as mAb114, is likely to be used in the current Ebola outbreak in DRC.

Synthetic and natural alternatives to traditional antibodies offer more control, specificity, and reproducibility. 

Mice receiving the treatment produced their own monoclonal antibodies and survived infection with the life-threatening pathogen Pseudomonas aeruginosa.